JAMA

06/05/2026

Med News: The World Health Organization’s first report on ni****ne pouches warns that companies may be using marketing tactics that attract youth and adults who don’t already use to***co. Read more about ni****ne pouch promotional strategies across the globe—and regulations that may help limit their harm.

This Medical News article discusses a World Health Organization report on marketing tactics used to increase global ni****ne pouch uptake.

06/05/2026

Med News: New research suggests that may take a different form in people with severe obesity, featuring weakened heart muscle contractions. 🫀 The findings highlight the importance of recognizing the distinct disease mechanisms of HFpEF in patients with severe obesity, which may lead to more targeted treatments.

This Medical News article discusses a new study that found weakened heart muscle cell contractions in patients with heart failure with preserved ejection fraction and very high body mass index.

06/05/2026

Presented today at :

Among adults with chronic ( ) due to glomerular diseases, finerenone slowed eGFR decline, reduced albuminuria, and lowered risk of kidney failure, with consistent benefits across disease subtypes and in those using inhibitors.

🔗 https://ja.ma/4x0RzrU

📊 Research Summary: Finerenone slowed eGFR decline, reduced albuminuria, and lowered risk of kidney failure or ≥40% eGFR decline in adults with chronic kidney disease ( ) due to glomerular diseases, with similar safety profile to placebo.

🔗 https://ja.ma/43hVS4v

06/05/2026

💬 Viewpoint by Susan Ott, MD: Although many individuals with remain untreated even after fracture, controversies persist regarding prevention strategies.

Recent US Food and Drug Administration regulatory changes allow osteoporosis drugs to be approved based on bone density, a surrogate marker, rather than clinical fracture reduction, aiming to reduce trial duration and facilitate medication development.

However, reliance on bone density as a surrogate may miss adverse outcomes, as not all agents with positive bone effects reduce fractures. Longer trials may better capture long-term safety and efficacy, improve patient education, and consider nonpharmacologic options such as hip protectors and thiazide diuretics.

https://ja.ma/4ubnlzJ

06/05/2026

Among adults with uncomplicated , 44% of adults treated with antibiotics had an appendectomy at 10 years, with 56% avoiding recurrence and surgery.

While a higher complication rate was observed in patients who underwent open appendectomy, contemporary approaches are likely to yield different risk profiles.

The study highlights the importance of risk-benefit analysis and shared decision-making regarding treatment options for appendicitis.

📽️ Watch the video and read the full article: https://ja.ma/4uR2nr0

06/05/2026

💬 Perspective by Daniel Lieberman, PhD, Daniel Aslan, PhD, and Steven Heymsfield, MD: Although -1 receptor agonists have transformed approaches to , most patients discontinue use within one year and are at risk for rapid weight regain.

Exercise at appropriate doses achieves high efficacy for weight control and preservation of fat-free mass, yet rarely succeeds in real-world practice due to low adherence.

are encouraged to routinely assess physical activity levels, communicate the health benefits of exercise, and collaborate with patients to mitigate barriers by creating personalized, feasible activity plans, potentially involving allied health professionals.

https://ja.ma/3PWrSZ1

06/05/2026

💬 Perspective: For-profit whole-body screening of the general adult population is not endorsed by evidence-based guidelines, given the lack of proven benefit and the likelihood that cumulative harms—including anxiety, invasive procedures, and unnecessary treatment—outweigh potential advantages.

Most incidental detections are low-risk and rarely improve outcomes, while aggressive disease is infrequently impacted by screening. Data from prior screening initiatives indicate increased diagnoses without mortality benefit and notable complications, supporting that individuals in the general population are more likely to be harmed than helped by elective whole-body MRI screening.

https://ja.ma/4ofiNHy

06/05/2026

📊 Research Summary: Finerenone slowed eGFR decline, reduced albuminuria, and lowered risk of kidney failure or ≥40% eGFR decline in adults with chronic kidney disease ( ) due to glomerular diseases, with similar safety profile to placebo.



https://ja.ma/49H7fXq

06/05/2026

"In India, [ -1 receptor agonists] are now sold at as low as 14% of the list price. Slowly but surely, we will get there with sufficient amounts and much lower prices."

Jens Juul Holst, MD, PhD, shares his perspective while attending the on .

This year’s JAMA Summit convened thought leaders to address the challenges and opportunities shaping the future of obesity treatment.

JAMA thanks the AMA Foundation for its generous support in the organization of the 2026 JAMA Summit.

https://ja.ma/4uLQ0MX

06/05/2026

Among patients with chronic ( ) due to glomerular diseases, —a nonsteroidal mineralocorticoid receptor antagonist—slowed the annual decline in estimated glomerular filtration rate (eGFR), reduced albuminuria, and lowered the risk of kidney failure or substantial loss of kidney function compared with placebo.

Effects were consistent across subtypes, including immunoglobulin A nephropathy, focal segmental glomerulosclerosis, and membranous nephropathy, and were observed in those receiving background renin-angiotensin system blockade and sodium-glucose cotransporter 2 ( ) inhibitors.



https://ja.ma/4uUti5x